In the latest trading session, 2.01 million CytomX Therapeutics Inc (NASDAQ:CTMX) shares changed hands as the company’s beta touched 1.21. With the company’s most recent per share price at $4.46 changing hands around $0.03 or 0.71% at last look, the market valuation stands at $303.99M. CTMX’s current price is a discount, trading about -31.17% off its 52-week high of $5.85. The share price had its 52-week low at $1.04, which suggests the last value was 76.68% up since then. When we look at CytomX Therapeutics Inc’s average trading volume, we note the 3-month average coming to 4.63 million.
CytomX Therapeutics Inc (NASDAQ:CTMX) trade information
Instantly CTMX is in green as seen in intraday trades today. With action 177.10%, the performance over the past five days has been green. The jump to weekly highs of 5.85 added 0.71% to the stock’s daily price. The company’s shares are showing year-to-date upside of 187.83%, with the 5-day performance at 177.10% in the green. However, in the 30-day time frame, CytomX Therapeutics Inc (NASDAQ:CTMX) is 116.57% up.
CytomX Therapeutics Inc (CTMX) estimates and forecasts
Data shows that the CytomX Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 281.31% over the past 6 months, a -2,400.00% in annual growth rate that is considerably lower than the industry average of 13.00%. Year-over-year growth is forecast to reach -12.60% down from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 22.02M. 6 analysts are of the opinion that CytomX Therapeutics Inc’s revenue for the current quarter will be 21.43M. The company’s revenue for the corresponding quarters a year ago was 23.5M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -6.30%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 67.21%. The 2024 estimates are for CytomX Therapeutics Inc earnings to decrease by -4286.00%, but the outlook for the next 5-year period is at -0.90% per year.
